HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Aleix Prat(Hospital Clínic de Barcelona), Mothaffar F. Rimawi(Baylor College of Medicine), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Begoña Bermejo(Hospital Clínico Universitario de Valencia), Carolina Gutiérrez(Baylor College of Medicine), Antonio C. Wolff(Johns Hopkins University), Carmine De Angelis(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Antonio Llombart‐Cussac(MedSIR (Spain)), Ian E. Krop(Yale Cancer Center), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Roberta Fasani(Vall d'Hebron Institute of Oncology), Tomás Pascual(Breast Cancer Research Foundation), Andres Forero(University of Alabama at Birmingham), Javier Cortés(Villa Maria Hospital), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Joel S. Parker(University of North Carolina at Chapel Hill), Patricia Galván(Vall d'Hebron Institute of Oncology), Jamunarani Veeraraghavan(Baylor College of Medicine), Brent N. Rexer(Vanderbilt University Medical Center), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Susan G. Hilsenbeck(Baylor College of Medicine), Miguel Izquierdo(University of Amsterdam), Jorge S. Reis‐Filho(AstraZeneca (France)), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Vanessa Rodrik-Outmezguine(Novartis (Switzerland)), Maria Vittoria Dieci(Istituto Oncologico Veneto), Anne C. Pavlick(Baylor College of Medicine), Gaia Griguolo(University of North Carolina at Chapel Hill), Serafín Morales(Hospital Universitari Arnau de Vilanova), María Vidal(Inserm), Tao Wang(Pfizer (United States)), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 168
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k